Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy

Area of Science:

• Oncology
• Immunology
• Nanomedicine

Background:

• Metastatic colorectal cancer (mCRC) presents significant challenges due to low immunogenicity and an immunosuppressive tumor microenvironment.
• Current immune checkpoint blockade therapies are ineffective for most mCRC cases, necessitating novel immunomodulatory strategies.

Purpose of the Study:

• To review the immunological hallmarks of mCRC metastases and identify organ-specific immune evasion mechanisms.
• To categorize and analyze emerging nano-immunotherapeutic strategies for mCRC treatment.
• To evaluate the translational potential and clinical feasibility of these nanomedicine approaches.

Main Methods:

• Systematic categorization of nano-immunotherapies into four classes: tumor vaccines, nanocarrier-mediated therapies, tumor microenvironment reprogramming, and immunogenic cell death induction.
• Analysis of mechanistic rationale, preclinical evidence, and mCRC-specific barriers for each strategy.
• Evaluation of translational landscape, clinical feasibility, and associated challenges.

Main Results:

• Identified organ-specific immune evasion mechanisms and molecular targets in mCRC metastases.
• Detailed four classes of nano-immunotherapies, including nanoparticle vaccines, nanocarrier-based checkpoint modulation, TME reprogramming, and ICD induction.
• Highlighted challenges in nanoparticle pharmacokinetics, immune toxicity, and patient stratification.

Conclusions:

• Nano-immunotherapy holds promise for transforming immune-cold mCRC tumors into immunologically responsive ones.
• Rational nanomedicine design is crucial for advancing precision immunotherapy in mCRC.
• Further research is needed to address translational and clinical challenges for effective patient treatment.